Biotechnology
Pacylex and Heidelberg Pharma Present Promising Zelenirstat ADC Data at World ADC Conference
Pacylex Pharmaceuticals and Heidelberg Pharma are presenting data showing zelenirstat's potential as a novel antibody drug conjugate payload, demonstrating significantly increased potency against breast and prostate cancer cells compared to oral administration alone.
GeoVax Relocates Headquarters and Labs to Atlanta Area to Fuel Growth and Pipeline Advancement
GeoVax Labs is relocating its corporate headquarters and laboratory operations to new Atlanta-area facilities, positioning the clinical-stage biotechnology company for accelerated growth, late-stage development, and future commercialization of its cancer and infectious disease therapies.
Quantum BioPharma Announces Private Placement to Strengthen Voting Control and Fund Operations
Quantum BioPharma Ltd. is conducting a $750 private placement that will significantly increase voting control for its key executives while providing working capital for its neurodegenerative and metabolic disorder treatments.
BIO CEO Warns U.S. Could Lose Biotech Leadership to China Within Two Years
GeoVax Labs calls for urgent policy action following Biotechnology Innovation Organization CEO John Crowley's warning that China could overtake U.S. biotech leadership within two years, highlighting the need for vaccine platform diversity, onshoring manufacturing, and protecting immunocompromised populations.
Helix BioPharma Narrows Losses Amid Strategic Shift to Lung Cancer Focus
Helix BioPharma reported reduced financial losses for fiscal 2025 while implementing a strategic pivot to focus exclusively on developing its L-DOS47 treatment for non-small cell lung cancer in combination with immunotherapy.
Soligenix ThermoVax Technology Addresses Critical Vaccine Stability Challenge in Epidemic Response
Soligenix's development of thermostable vaccines that remain stable at high temperatures could significantly reduce global vaccine wastage and improve deployment in outbreak regions where cold chain infrastructure is limited.
Renaissance BioScience Recognized Among Canada's Top Food Technology Innovators
Renaissance BioScience has been selected as a winner in the inaugural Foodtech Frontier Award program for its innovative yeast-based solutions that address critical food industry challenges while offering environmental benefits.
Octane's 2025 Medical Innovation Forum to Spotlight Health Longevity Breakthroughs
Southern California's premier innovation accelerator Octane will host its 2025 Medical Innovation Forum featuring groundbreaking longevity research and wellness innovations that could transform future healthcare approaches.
Aditxt Subsidiary Pearsanta Launches Clinical Study for Blood-Based Endometriosis Diagnostic
Aditxt's subsidiary Pearsanta has begun enrolling patients in a clinical study for a novel blood-based endometriosis test that could provide earlier, non-invasive detection compared to current surgical methods.
Annovis Bio Secures $3.4 Million in Registered Direct Offering to Advance Neurodegenerative Disease Therapies
Annovis Bio has raised $3.4 million through a registered direct offering to fund development of treatments for Alzheimer's and Parkinson's diseases, providing crucial capital for advancing late-stage clinical programs targeting neurodegeneration.
Lantern Pharma Partners with Hoth Therapeutics to Deploy AI Platform for Blood-Brain Barrier Prediction
Lantern Pharma's AI platform PredictBBB.ai, which boasts 94% accuracy in predicting drug penetration of the blood-brain barrier, is being deployed through a partnership with Hoth Therapeutics to accelerate neurological drug development.
Nutriband's AVERSA Fentanyl Patch Advances Toward 2026 FDA Submission with $200M Market Potential
Nutriband Inc. is progressing with its abuse-deterrent fentanyl patch technology that could generate up to $800 million in annual sales while addressing the opioid crisis through tamper-resistant transdermal delivery.
New Melanoma Test Shows Three-Fold Improvement in Predicting Lymph Node Metastasis Risk
The Merlin CP-GEP test accurately stratifies melanoma patients by sentinel node metastasis risk, potentially reducing unnecessary surgical procedures through improved personalized care.
NanoViricides Reports NV-387 Shows Strong Antiviral Activity Against Measles in Preclinical Studies
NanoViricides' clinical lead drug candidate NV-387 demonstrated potent antiviral effects against Measles virus with significant lung protection and extended survival in animal models, potentially offering the first approved treatment for a disease that currently has no specific antiviral therapy.
Oragenics Regains NYSE Compliance Following $16.5 Million Funding Round for Concussion Treatment Development
Oragenics Inc. has regained full compliance with NYSE American listing standards following a successful $16.5 million public offering, securing financial stability to advance its intranasal concussion treatment through critical clinical trials.
Danaher Exceeds Expectations with Strong Third Quarter 2025 Performance
Danaher Corporation reported better-than-expected third quarter 2025 results with 4.5% revenue growth and strong cash flow generation, driven by bioprocessing momentum and respiratory revenue at Cepheid, demonstrating the company's resilience in the healthcare sector.
Kairos Pharma Reports Positive Interim Phase 2 Results for ENV-105 in Advanced Prostate Cancer
Kairos Pharma announced positive interim Phase 2 data showing ENV-105 combined with apalutamide achieved clinical benefit in 86% of metastatic castration-resistant prostate cancer patients, potentially addressing treatment resistance in advanced disease.
Oncotelic Therapeutics Fills Critical Gaps in Cancer Treatment with RNA and Small-Molecule Therapies
Oncotelic Therapeutics is developing innovative RNA therapeutics and small-molecule drugs to address unmet needs in rare pediatric cancers and resistant solid tumors where traditional treatments have fallen short.
ABVC BioPharma Recognized as Promising Biotech Investment Amid Strong Financial Performance and Clinical Progress
ABVC BioPharma's recognition as a top biotech investment opportunity highlights the company's significant financial growth and advancing clinical pipeline across central nervous system disorders and oncology treatments.
Pelage Pharmaceuticals Raises $120 Million for Revolutionary Hair Growth Therapy
Pelage Pharmaceuticals secured $120 million in Series B funding to advance its novel regenerative hair growth therapy PP405, which could transform treatment for millions suffering from hair loss by reactivating dormant hair follicle stem cells.
Annovis Bio Secures $6 Million in Registered Direct Offering to Advance Neurodegenerative Disease Therapies
Annovis Bio has closed a $6 million registered direct offering to fund development of treatments for Alzheimer's and Parkinson's diseases, providing crucial capital for advancing late-stage clinical programs targeting neurodegeneration.
GeoVax Reports Positive Interim Results for Multi-Antigen COVID-19 Vaccine in Immunocompromised Patients
GeoVax Labs announced promising Phase 2 clinical trial results showing its multi-antigen COVID-19 vaccine candidate demonstrates strong safety and robust T-cell responses in immunocompromised patients, potentially addressing a critical gap in protection for vulnerable populations.
Humacyte Secures $60 Million in Oversubscribed Stock Offering to Advance Bioengineered Tissue Platform
Humacyte's successful $60 million capital raise provides critical funding to accelerate development of its universally implantable bioengineered human tissues, which have received multiple FDA designations and could transform treatment for vascular trauma, dialysis access, and other medical conditions.
eXoZymes Partners With B2i Digital to Showcase Cell-Free Biomanufacturing Platform
eXoZymes Inc. has been selected as a B2i Digital Featured Company, highlighting its cell-free, AI-guided enzyme platform that offers a scalable alternative to traditional petrochemical processes and synthetic biology methods.
TransCode Therapeutics Advances Cancer Treatment with Successful Phase 1a Trial of TTX-MC138
TransCode Therapeutics has successfully completed Phase 1a clinical trials for TTX-MC138, an RNA-based cancer treatment targeting metastatic disease, showing promising safety results and disease stabilization in nearly half of patients, advancing to Phase 2 evaluation.
Soligenix Secures $7.5 Million in Public Offering to Advance Rare Disease Pipeline Through 2026
Soligenix has closed a $7.5 million public offering that extends its financial runway through 2026, enabling continued advancement of its rare disease treatment pipeline including late-stage clinical trials and regulatory milestones.
MindWalk Holdings Authorizes $2.3 Million Share Buyback Program
MindWalk Holdings announced a 2.3 million share repurchase program reflecting management's confidence in the bio-native AI company's long-term value and strategic positioning in drug discovery innovation.
GeoVax Executives Pursue European Partnerships to Advance Vaccine and Cancer Therapy Development
GeoVax Labs is intensifying European partnership efforts to accelerate development of vaccines for mpox, COVID-19, and cancer therapies, addressing critical global health needs.
Lifordi Immunotherapeutics Reports Promising Preclinical Data for Autoimmune Treatment LFD-200
Lifordi Immunotherapeutics will present new preclinical data showing its antibody drug conjugate LFD-200 delivers glucocorticoids directly to immune cells with sustained anti-inflammatory effects and no systemic toxicity, potentially offering a safer treatment option for autoimmune diseases.
Andrew Hillman Grant Launches to Support Next Generation of Biotech Innovators
The Andrew Hillman Grant for Biotech offers $1,000 to undergraduate students pursuing biotechnology careers, representing a strategic investment in future healthcare and technology leaders.